本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
CHONGQING, China, Feb. 3, 2026 /PRNewswire/ -- In 2025, SERES NEV sales exceeded 470,000 units, cementing the company's position as industry leader. The flagship AITO brand especially stood out, with over 420,000 vehicles delivered throughout the year—making it the top-selling luxury brand in the Chinese market. This achievement underscored AITO's leadership in China's high-end new energy market and the rise of Chinese brands in the premium automotive segment. Cumulative Luxury Car Brand Sales in the Chinese Market, 2025 AITO's sustained success is no accident. Its "blockbuster" appeal stemmed from precise product positioning, robust capabilities, and a strong reputation among users. All of this resulted in a strong product lineup in the CNY 200,000 to 600,000 price range. The AITO M9 proved to be a true phenomenon, with cumulative deliveries exceeding 270,000 units and a 21-month run as the top model in its segment. At the same time, the AITO M8 and M7 also established leading positions in their respective segments: the M8 was the best-selling model in the CNY 400,000 segment for six consecutive months, and cumulative deliveries of the M7 surpassed 400,000 units, setting a benchmark in the market. Together, these three flagship models drove brand momentum and reinforced AITO's competitive edge in the high-end market. AITO Achieves Record Growth Beyond sales, AITO's sterling reputation and high vehicle value retention continued to fuel its strong market performance. AITO surpassed traditional luxury brands like BMW and Audi in the Chinese automotive market research firm LandRoad's New Energy Vehicle Brand Index. With an average vehicle price of CNY 400,000, it also overtook the BBA group (BMW, Benz, and Audi) to become China's leading luxury automotive brand. This milestone signified both AITO's dominance in scale and a significant rise in brand reputation, customer trust, and value, establishing it as the top choice for discerning consumers. Looking ahead, as it expands globally, advances its technologies, and broadens its portfolio, AITO will further strengthen its leadership in the luxury NEV market. With growing confidence, AITO is set to drive greater breakthroughs for Chinese automotive brands worldwide.
ECARX Zenith delivers integrated services on a single SoC, supporting Android 16, Google Automotive Services (GAS) and S-Core open-source middleware, supporting advanced software-defined vehicle architectures LONDON, Feb. 3, 2026 /PRNewswire/ -- ECARX Holdings Inc. (Nasdaq: ECX) ("ECARX" or the "Company"), a global mobility tech provider, debuted a pre-production sample of its Zenith computing platform at CES 2026 in Las Vegas. This innovative and ground-breaking system offers a unified high-performance intelligent cockpit and ADAS architecture, powered by the Snapdragon® Elite (SA8797) platform for automotive from Qualcomm Technologies, Inc. This platform reflects the latest progress in the ECARX R&D roadmap, developing a diverse portfolio of solutions to allow seamless customization for automakers for global deployment. Developed in collaboration with Qualcomm Technologies and leveraging the powerful Qualcomm Oryon™ CPU, Qualcomm® Adreno™ GPU and Qualcomm® Hexagon™ NPU combination, ECARX Zenith showcases the capabilities of the Snapdragon Elite platform for automotive to run mixed-criticality intelligent cockpit and ADAS functionalities simultaneously on a single, high-performance system on chip (SoC). The platform demonstration features an immersive, premium-feeling 3D launcher, 5K ultra-high-resolution display, and Google Automotive Services (GAS) ecosystem integration. The Zenith platform shown at CES also offers a safety-critical 3D instrument cluster display built on QNX 8.0, showcasing mixed-criticality platform support, as well as advanced Level 2++ ADAS, built on S-Core open-source middleware in collaboration with Qorix. Beyond its current configuration, Zenith's modular design will allow automakers to scale performance based on their tailored capability requirements. The architecture supports additional hardware modules for Level 3+ autonomy and advanced telematics, providing a long-term, upgradeable solution. ECARX plans to use the Snapdragon Elite platform for automotive to develop a comprehensive portfolio of single-chip and flagship dual-chip integrated solutions. The Zenith computing platform is currently being demonstrated as a sample, with production expected to begin in 2027. Mr. Ziyu Shen, Chief Executive Officer and Chairman of ECARX, commented, "ECARX has been committed to the development of cutting-edge automotive intelligent technologies since inception. CES provided an opportunity for ECARX and our partners to show not just how our platforms are already delivering value to drivers and automakers in the 10 million+ vehicles on the road worldwide with our technologies, but also the enormous possibilities our innovative R&D roadmap is creating. "With Qualcomm Technologies' Snapdragon Elite platform for automotive, we believe the power and modular flexibility of the Zenith computing platform will make it a cornerstone for automakers building the next generation of automotive experiences. We look forward to driving further innovation and new breakthroughs together with our eco-partners on a global scale." Qualcomm, Adreno, Hexagon, Qualcomm Oryon and Snapdragon are trademarks or registered trademarks of Qualcomm Incorporated.Snapdragon, Qualcomm Oryon, Qualcomm Adreno and Qualcomm Hexagon are products of Qualcomm Technologies, Inc. and/or its subsidiaries. About ECARX ECARX (Nasdaq: ECX) is a global automotive technology provider with capabilities to deliver turnkey solutions for next–generation smart vehicles, from the system–on–a–chip (SoC) to central computing platforms and software. As automakers develop new vehicle architectures, ECARX is developing full–stack solutions to enhance the user experience while reducing complexity and cost. Founded in 2017 and listed on the Nasdaq in 2022, ECARX now has over 1,500 employees based in 13 major locations in China, UK, USA, Brazil, Singapore, Malaysia, Sweden and Germany. To date, ECARX products can be found in approximately 10 million vehicles worldwide.
GUANGZHOU, China, Feb. 2, 2026 /PRNewswire/ -- As 2026 begins, GAC takes the lead with an "impressive start" performance: in January this year, its overseas wholesale sales surged 69% year-on-year, continuing the robust growth momentum of the past two years and laying a solid foundation for the 2026 overseas sales target of "300,000 units". Among them, the AION V set a new monthly retail sales record since its overseas launch. In terms of regional market highlighs, GAC Flourishing Across the Globe: In the Asia-Pacific region, GAC consistently ranks among the top three Chinese brands in sales volume in the Cambodian market; In Europe, retail sales in Greece in January surged 233% month-on-month compared with December, as brand recognition steadily rises with market performance. In the Middle East, the GAC GS8 ranked third among Chinese brands in terms of sales of large SUVs in Kuwait, verifying its product competitiveness in the segment. In the Americas, GAC ranks first sales among Chinese brands in the Dutch Caribbean market of Panama; In Colombia, GAC retains its position among the top three in overall EV sales, with its regional influence continuing to expand. Behind the strong sales growth lies the continuous launch of high-quality products and solid construction of systematic capabilities. In terms of product layout, the GAC S7 and AION i60, which were launched in China in 2025, are set to make their overseas debut soon, accelerating the product rhythm. These two popular models, highly recognized in the domestic market, are expected to become "growth drivers" for GAC's overseas product matrix. In terms of system construction, the "Thousand-Network Plan" continues to advance, with 20 new overseas outlets added in January, bringing the total global network to 650, covering 86 countries and regions across 5 major regions: Asia-Pacific, Middle East and Africa, Europe, CIS and Central and South America, providing sufficient network support for future sales growth. 5 overseas production have been completed and put into operation, while the AION UT project has reached a key milestone with the successful roll-off of the first prototype from Magna's factory in Austria. Localization production projects in Cambodia, Brazil and Egypt are also in progress. For further information about GAC, please visit: https://www.gacgroup.com/en or follow us on social.
- Secured 9.17 billion USD in orders, exceeding the core components target (7.45 billion USD) by 23% despite EV chasm- Diverse advanced portfolio, including Battery Systems Assembly (BSA) and next-gen electronic components, drove results- Customer base expanded from major automakers in North America and Europe to emerging markets such as China and India- Overseas orders accelerating on the back of leading technologies, with a target of 11.84 billion USD in core components (8.97 billion USD) and modules this year SEOUL, South Korea, Feb. 2, 2026 /PRNewswire/ -- Hyundai Mobis announced that it secured 9.17 billion USD in orders from global automakers last year, excluding Hyundai Motor and Kia. This figure exceeds its original target of 7.45 billion USD by 23%. These results were driven by a combination of large-scale new orders for electrification components, expanded supply of high value-added electronic components, and proactive market penetration in emerging economies such as China and India, the company said on 2. The achievement is particularly noteworthy given that many global automakers have been revising their new vehicle launch plans amid the ongoing EV chasm. The results reflect Hyundai Mobis's sustained investment in R&D over recent years to strengthen its leadership in advanced technologies, which is now translating into tangible overseas orders from global customers. For this year, Hyundai Mobis has set an aggressive global order target of approximately 11.84 billion USD, representing an increase of about 30% from last year. The target reflects continued core-components orders at a similar level to last year, alongside consideration of large-scale module orders, supported by region-specific sales strategies and close collaboration with key customers. Large Electrification Components and Module Orders from North America and Europe Drive Strong Performance Last year, Hyundai Mobis secured orders from two major global customers in North America and Europe to supply key electrification components such as Battery Systems Assembly (BSA) and chassis modules. In line with contractual practices, confidentiality requirements, and potential changes prior to mass production, the company did not disclose customer names or detailed contract values. However, these orders are understood to account for a significant portion of last year's total order volume. Hyundai Mobis expects long-term partnership benefits from its electrification and module orders. Large-scale components such as BSAs and chassis modules require joint investments in production facilities and logistics systems, often resulting in supply contracts lasting 10 to 20 years or more. In fact, Hyundai Mobis has maintained a close partnership with Chrysler (now Stellantis) for over 20 years since it began supplying chassis modules to the company in 2005. Broad Electronic Components Portfolio Converts into Orders Hyundai Mobis also delivered solid order results in electronic components, a high value-added business segment. It secured orders for advanced Human-Machine Interface (HMI) products from another major North American customer and agreed to expand the supply of sound systems to a sedan-focused brand.*HMI: display systems that provide various driving information through communication between humans and machines (vehicles). The next-generation HMI secured through this order is a flagship electronic component that Hyundai Mobis is cultivating as a global market leader, distinguished by its advanced technologies that set it apart from competitors. The company is currently engaged in active discussions with other global customers to further expand orders. Sound systems are another product category where Hyundai Mobis has been increasing its presence among premium brands. While overseas automakers have traditionally favored domestically developed sound systems, Hyundai Mobis successfully overcame this preference through technological competitiveness. Meanwhile, Hyundai Mobis has diversified its customer base for core components such as braking, steering, and safety systems in emerging markets including China and India. In India, the company's tailored component supply strategy for local brands proved effective as their market share continued to rise. In China as well, Hyundai Mobis secured new orders from local EV brands by leveraging its differentiated sourcing competitiveness. Jae-mok Cho, Head of Global Sales at Hyundai Mobis, said, "While uncertainty in the external business environment is expected to persist this year, we plan to step up our order-acquisition efforts and surpass last year's performance by leveraging our core competitiveness in electrification and electronic components." About Hyundai MobisHyundai Mobis is the global no. 6 automotive supplier, headquartered in Seoul, Korea. Hyundai Mobis has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company's products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting, and automotive electronics. Hyundai Mobis operates its R&D headquarters in Korea, with four technology centers in the United States, Germany, China, and India. For more information, please visit the website at http://www.mobis.com. Media Contact Choon Kee Hwang: ckhwang@mobis.com Jihyun Han: jihyun.han@mobis.com
Strategic expansion positions Singapore as a strategic arm for healthcare logistics in the APAC region. DHL Group invests €10 million in a new pharmaceutical hub in Singapore to enhance international logistics and healthcare logistics infrastructure across the Asia-Pacific region. The expansion bolsters specialised services for shipping medicinal products, clinical trials, and medical devices via DHL Medical Express and a dedicated medical courier framework. This initiative contributes to a €500 million regional investment in health logistics by 2030, addressing the growing industry demand for reliable, temperature-controlled shipping solutions. SINGAPORE, Feb. 2, 2026 /PRNewswire/ -- DHL Group has announced the expansion of its life sciences arm—DHL Health Logistics—with the development of a €10 million Pharmaceutical Hub in Singapore. This investment bolsters regional Life Sciences and Healthcare (LSHC) infrastructure. As a global leader in international logistics, DHL Express provides extensive network connectivity and operational expertise. In the life sciences and healthcare sector, the requirement for reliable and secure logistics continues to grow as global supply chains become increasingly complex. Addressing the Growing Needs of a Modern Healthcare Supply Chain The demand for specialised healthcare logistics is rising, driven by global health challenges, an ageing population, and the development of advanced therapies. In Singapore, the biomedical sector produces goods valued at nearly S$38 billion for global markets. The industry requires a health logistics infrastructure capable of accommodating the increasing volume and complexity of life-saving products distributed from regional hubs to the rest of the world. In the modern healthcare supply chain, every step impacts patient well-being and critical research. Innovation in medical shipping is no longer optional; maintaining stringent temperature control for pharmaceuticals and navigating the regulatory demands of medical devices is critical. By aligning with Singapore's strategic vision, DHL provides the precision and reliability to support scientific progress and ensure that products are handled as required by the healthcare ecosystem. DHL's Reach in Life Sciences & Healthcare DHL leverages an extensive global network spanning over 220 countries and territories to facilitate seamless international logistics. Through DHL Health Logistics and its services, the group utilises dedicated healthcare hubs and warehouses within a GDP-compliant infrastructure. This allows the group to support the global healthcare ecosystem with a combination of high-capacity transport and local handling. With its Medical Express service (WMX), DHL Express ensures secure and compliant transport of sensitive shipment such as investigational drugs, medicinal products, and active pharmaceutical ingredients (API). The service offers a range of temperature-controlled solutions, from ambient to ultra-deep frozen (below -180°C). All solutions are fully compliant with UN 3373 and IATA Dangerous Goods standards. Supported by a medical courier framework, DHL Health Logistics is optimised for urgent medical needs through priority delivery and time-definite collection schedule. All shipments are managed by certified specialists to ensure adherence to international healthcare standards and rigorous quality management certifications. Setting Up the Next Vantage Point for Healthcare Logistics DHL has strengthened its healthcare logistics capabilities in Singapore with the addition of the €10 million pharmaceutical hub, featuring specialised temperature zones and GMP-compliant infrastructure. Located near Tuas Biomedical Park, this facility reinforces Singapore's position as a strategic hub for Asia-Pacific, offering efficient connectivity to Changi Airport and Tuas Mega Port. These investments are part of a broader commitment to invest €500 million into regional health logistics by 2030, supporting resilience in global healthcare supply chains. Leaving a Positive Impact on Life Sciences The expansion of DHL Health Logistics is intended to support improved patient outcomes by facilitating timely delivery of critical medicines and medical devices. By strengthening its infrastructure, DHL provides the reliability required for shipping medicine and healthcare products through every stage of the supply chain: Pharmaceutical Logistics: DHL maintains GxP compliance and operational efficiency through strategic investments like the new Singapore Pharma Hub, which manages demand surges and large-scale vaccine distribution. Clinical Trial Logistics: The network provides specialised handling for Investigational Medicinal Products (IMP) and biological samples, supported by a global infrastructure of GMP-compliant depots and temperature-monitored shipping. Medical Device Logistics: "Device Final Mile" facilitates the delivery of medical devices and equipment directly to healthcare facilities. Aftermarket support maximises equipment uptime by supplying spare parts and repairs. Speciality Pharmaceutical Logistics: DHL ensures cold chain integrity across a spectrum of requirements, from ambient to cryogenic (-196°C) environments, utilising real-time monitoring to mitigate risks for sensitive shipments. Consumer Healthcare Logistics: To maintain product availability, DHL utilises automation and omnichannel fulfilment to bridge the gap between manufacturers and retail platforms. Aid and Relief Logistics: Leveraging a global network and dedicated Control Towers, DHL provides rapid response capabilities and procurement expertise for humanitarian missions and disaster relief. This investment is a cornerstone of the DHL Group Strategy 2030, which focuses on expanding digitalisation, sustainability, and specialised infrastructure. By aligning these innovations with the evolving needs of the life sciences industry, DHL aims to be a trusted logistics partner for healthcare manufacturers and researchers worldwide. This vision also reaffirms DHL Express's role as a pioneer in international logistics, transforming supply chains into reliable lifelines for patients worldwide. Healthcare and life science partners are invited to collaborate with DHL to deliver reliable, innovative shipping solutions that ensure the safe, efficient delivery of medicinal products worldwide. About DHL DHL – The logistics company for the world DHL is the leading global brand in the logistics industry. Our DHL divisions offer a portfolio of logistics services ranging from national and international logistics, e-commerce shipping and fulfilment solutions, international express, road, air, and ocean transport, to industrial supply chain management. With approximately 400,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialised solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is positioned as "The logistics company for the world". DHL is part of DHL Group. The Group generated revenues of approximately 84.2 billion euros in 2024. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. DHL Group aims to achieve net-zero emissions logistics by 2050.
BEIJING, Feb. 2, 2026 /PRNewswire/ -- On January 27, the China Automobile Dealers Association and Jingzhengu, released the 2025 China Automotive Resale Value ranking Report. GAC's brands AION and GAC achieved outstanding results, with the M8 and GS8 topping resale value rankings in their respective segments, demonstrating the strong market recognition and value of "Quality GAC." As competition in China's automotive market intensifies, resale value has become a critical measure of a vehicle's long-term value and reputation. Jointly issued by the China Automobile Dealers Association and Jingzhengu, the annual resale value report has steadily enhanced its assessment methodology, aiming to establish "resale value" as a "shared metric" among manufacturers, distributors, consumers, and policymakers. It not only reflects a vehicle's value retention, but also meaningfully influences consumer purchase decisions. GAC led the rankings with a commanding advantage, ranking first among Chinese brands in three-year resale value. Several models achieved top positions across key segments. In the MPV segment, the M8 ranked first among Chinese-brand MPVs in three-year resale value, with the M6 placed third. The E8 and E9 took the top two spots in one-year resale value for Chinese-brand plug-in hybrid MPVs, underlining GAC's expertise and market credibility in the MPV sector. In the SUV segment, the GS8 ranked first among Chinese-brand mid-size SUVs for three-year resale value, while the GS3 EMZOOM placed third in the compact SUV category. Meanwhile, the EMPOW and GA6 secured third and fourth place respectively in the compact and mid-size sedan categories, demonstrating comprehensive coverage of mainstream consumer segments and catering to diverse user value needs. AION also demonstrated strong residual value performance. The AION RT ranked second in one-year resale value among pure electric compact cars, while the AION Y placed third in three-year resale value for pure electric compact SUVs. Backed by the world's only NEV "Lighthouse Factory," AION ensures products with "zero defects and zero faults." In 2025, it achieved the top ranking in China's new energy vehicle quality for the third consecutive year, maintaining leading resale value and customer satisfaction. These achievements reflect GAC's strong manufacturing expertise and commitment to quality, as well as broad market recognition. Looking ahead, GAC will continue leveraging technology and a user-centric approach to enhance competitiveness, deliver higher-value mobility solutions, and lead the high-quality development of China's automotive industry.
A12 藝術空間
Transportation/Trucking/Railroad
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
